LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
| Autor: | Renouf, D.J., Knox, J.J., Kavan, P., Jonker, D., Welch, S., Couture, F., Lemay, F., Tehfe, M., Harb, M., Aucoin, N., Ko, Y-J., Tang, P., Ramjeesingh, R., Meyers, B.M., Kim, C., Schaeffer, D.F., Loree, J., Gill, S., Tu, D., O'Callaghan, C. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S1195-S1195 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|